SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHellenic Dynamics Regulatory News (HELD)

  • This share is currently suspended. It was suspended at a price of 0.95

Share Price Information for Hellenic Dynamics (HELD)

Share Price is delayed by 15 minutes
Get Live Data
0.95    0.00 (0.00%)
Bid:
0.00
Ask:
0.00
Spread: 0.00 (0.00%)
Market Cap: £1.40m
HELD Live PriceLast checked at - London Stock Exchange

Intraday Hellenic Dynamics Share Chart

Total Voting Rights

1 May 2024 12:00

RNS Number : 8340M
Hellenic Dynamics PLC
01 May 2024
 

01 May 2024

 

Hellenic Dynamics plc

 

("Hellenic Dynamics" or the "Company")

 

Total Voting Rights

 

 

Hellenic Dynamics Plc (LSE: HELD), a medical cannabis cultivator with a dedicated focus on producing tetrahydrocannabinol ("THC") dominant strains of medical cannabis flowers for the fast growing global medical cannabis markets announces as at close of business on 30 April 2024, the Company had 131,693,818 ordinary shares of 0.1p each in issue. Each ordinary share carries the right to one vote. The Company does not hold any shares in treasury.

 

This figure 131,693,818 may be used by shareholders as the denominator for the calculations by which they will determine whether they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure and Transparency Rules.

 

 

Enquiries:

 

Hellenic Dynamics plc

+44 (0)20 3818 7850

Davinder Rai

davinder@hellenicdynamics.com

Cairn Financial Advisers LLP

+44 (0)20 7213 0880

Emily Staples / Jo Turner

Peterhouse Capital

+44 (0)20 7469 0930

Lucy Williams / Charles Goodfellow

 

About Hellenic Dynamics plc

 

Founded in 2019, Hellenic Dynamics is specifically focused on the cultivation and supply of THC ("tetrahydrocannabinol") - dominant strains of medical cannabis flowers, destined for the growing global medical cannabis markets. Hellenic Dynamics' core strategy is to develop and operate its 40,000 square metre active cultivation licence from its 195,506 square metre facility located near Thessaloniki in Northern Greece. In full production, Hellenic Dynamics is capable of producing over 54,000 kg of dried flowers per annum.

 

Hellenic Dynamics will take advantage of its relatively low cost base resulting from a comparatively low cost of power, having its own running water supply and the labour rates for skilled and semi-skilled labour in Northern Greece.

 

26 European countries now allow medical cannabis via prescription and the European cannabis market is expected to reach €17.39 billion per annum by 2028. Sales of Hellenic Dynamics' dried THC-dominant cannabis flowers and extracts are initially intended for export into Europe, in addition to other international markets and domestically in Greece.

 

As the first medical cannabis cultivator to obtain a listing on the main market for listed securities of the London Stock Exchange, Hellenic is significantly different to the number of CBD (Cannabidiol) related companies that have appeared over the recent years. Hellenic Dynamics cultivates THC-dominant medical cannabis flowers. THC-dominant medical cannabis products are only available via a medical prescription. Medicinal cannabis has been approved for use both in the United Kingdom and Germany, plus 24 other European countries, for conditions including but not limited to chronic pain, intractable chemotherapy-related nausea, anxiety, insomnia, Tourette's syndrome, substance use disorder, multiple sclerosis, IBS, spinal cord treatment, lack of appetite due to HIV/AIDS, cachexia, anorexia and glaucoma.

 

For further information please visit our website www.hellenicdynamics.com 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TVRBGGDUDBGDGSB
12
Date   Source Headline
3rd Jul 202512:55 pmRNSFurther re: Winding-Up Petition
12th Feb 20255:45 pmRNSFurther re: Winding-Up Petition
12th Feb 20257:00 amRNSWinding-Up Petition
19th Dec 202411:35 amRNSFurther re: Winding-Up Petition
26th Nov 202410:00 amRNSWinding-Up Petition
15th Nov 20247:00 amRNSUpdate on €1 million loan
11th Nov 20241:30 pmRNSChange of Registered Office
7th Oct 20247:00 amRNSUpdate on receipt of €1 million loan
21st Aug 20243:30 pmRNSUpdate on receipt of €1 million loan
14th Aug 20247:00 amRNSUpdate on Petition and Related Party Transactions
1st Aug 20241:10 pmRNSWinding-Up Petition
1st Aug 20248:00 amRNSDelay to the publication of accounts & Suspension
15th Jul 20247:00 amRNSSettlement of Fees and Issue of Equity
8th Jul 202410:30 amRNSHolding(s) in Company
2nd Jul 20243:18 pmRNSHolding(s) in Company
2nd Jul 202410:45 amRNSFacility, Cultivation and Market Update
25th Jun 20247:00 amRNSDirectorate Changes
3rd Jun 20247:00 amRNSTotal Voting Rights
16th May 202411:30 amRNSFurther re: Mezzanine Loan
8th May 20249:00 amRNSPlacing & Issue of Equity
1st May 202412:00 pmRNSTotal Voting Rights
22nd Apr 20247:00 amRNSLong Term Loan Agreement
16th Apr 20242:00 pmRNSSettlement of Fees and Issue of Equity
28th Mar 20244:35 pmRNSTotal Voting Rights
28th Mar 20247:00 amRNSPart Discharge of Loan & Interest, Issue of Equity
22nd Mar 20247:00 amRNSHolding(s) in Company
4th Mar 20247:00 amRNSSettlement of Fees and Issue of Equity
23rd Jan 20242:00 pmRNSFirst Instalment of EU Grant
17th Jan 202411:00 amRNSLetter of intent for funding with Piraeus Bank S.A
28th Dec 20232:01 pmRNSHalf-year Report
19th Dec 20237:00 amRNSAgreement with The University of Patras
27th Nov 20237:00 amRNSCapital Reorganisation
23rd Nov 20237:00 amRNSNew Company Presentation and Facility Presentation
20th Nov 20234:30 pmRNSResult of General Meeting
17th Nov 20237:00 amRNSTimetable for the Proposed Capital Reorganisation
26th Oct 20237:00 amRNSMezzanine Loan and Posting of Circular
11th Oct 20237:00 amRNSCommencement of Cultivation
7th Sep 20237:00 amRNSNotice of AGM
31st Jul 202310:05 amRNSSuccessful Application for EU Grant
31st Jul 202310:00 amRNSAnnual Report for the period ended 31 March 2023
6th Jul 20234:55 pmRNSRepayment of Convertible Loan Note
13th Jun 20237:00 amRNSSigning of MoU with Demecan Holding
6th Jun 20237:00 amRNSBusiness Update
27th Mar 20237:00 amRNSAppointment of Katherine Fleming to Advisory Board
22nd Mar 20237:00 amRNSMemorandum of Understanding with ELGO-DIMITRA
21st Mar 20232:00 pmRNSPrice Monitoring Extension
17th Mar 20234:35 pmRNSPrice Monitoring Extension
14th Mar 20234:40 pmRNSSecond Price Monitoring Extn
14th Mar 20234:35 pmRNSPrice Monitoring Extension
16th Feb 202311:05 amRNSSecond Price Monitoring Extn
12

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.